A.P. Pharma, Inc.

A.P. Pharma reports income of $0.75 per share; phase III trial for APF530 initiated

Published in Pharma Investments, Ventures and Law Weekly, June 4th, 2006

A.P. Pharma, Inc., (APPA) reported financial results for the 3 months ended March 31, 2006 and that the company initiated a phase III clinical trial using APF530, its product candidate for the prevention of chemotherapy-induced nausea and vomiting.

During the quarter, the company completed the sale of its interests in royalties on sales of Retin-A Micro and Carac effective October 1, 2005. The company received $25 million at the closing of the transaction and is entitled to receive an additional $5 million on the satisfaction of certain predetermined milestones. As a result of the sale, no royalty revenues were recorded for the first quarter of 2006 compared with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly

Source: Pharma Investments, Ventures and Law Weekly (2006-06-04)

More Articles from Pharma Investments, Ventures and Law Weekly

Abiomed, Inc.
Abiomed reports revenue is up 28% to $13.8 million
Acadia Pharmaceuticals, Inc.
Acadia Pharmaceuticals reports quarterly loss of $9.5 million
Aceto Corp.
Aceto announces earnings per share of $0.11
Adherex Technologies, Inc.
Adherex announces US$6.5 million private placement
Adolor Corp.
Adolor reports loss of $0.42 per share
Adventrx Pharmaceuticals, Inc.
Adventrx Pharmaceuticals posts loss of $0.31 per share
More from this issue of Pharma Investments, Ventures and Law Weekly

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry